HeartBeam (BEAT) versus Its Rivals Head-To-Head Review

HeartBeam (NASDAQ:BEAT) is one of 58 public companies in the “MEDICAL INFO SYS” industry, but how does it compare to its peers? We will compare HeartBeam to related companies based on the strength of its institutional ownership, valuation, dividends, analyst recommendations, profitability, earnings and risk.

Volatility and Risk

HeartBeam has a beta of -0.86, indicating that its share price is 186% less volatile than the S&P 500. Comparatively, HeartBeam’s peers have a beta of 2.02, indicating that their average share price is 102% more volatile than the S&P 500.

Valuation & Earnings

This table compares HeartBeam and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
HeartBeam	N/A	-$21.01 million	-1.44
HeartBeam Competitors	$498.43 million	-$52.57 million	8.24

HeartBeam’s peers have higher revenue, but lower earnings than HeartBeam. HeartBeam is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares HeartBeam and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
HeartBeam	N/A	-571.06%	-353.09%
HeartBeam Competitors	-665.15%	-125.79%	-20.00%

Institutional & Insider Ownership

7.8% of HeartBeam shares are owned by institutional investors. Comparatively, 43.7% of shares of all “MEDICAL INFO SYS” companies are owned by institutional investors. 18.0% of HeartBeam shares are owned by company insiders. Comparatively, 17.2% of shares of all “MEDICAL INFO SYS” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for HeartBeam and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HeartBeam	1	2	4	1	2.63
HeartBeam Competitors	658	1038	2259	54	2.43

HeartBeam currently has a consensus target price of $4.80, suggesting a potential upside of 439.27%. As a group, “MEDICAL INFO SYS” companies have a potential upside of 64.61%. Given HeartBeam’s stronger consensus rating and higher possible upside, research analysts clearly believe HeartBeam is more favorable than its peers.

Summary

HeartBeam peers beat HeartBeam on 7 of the 13 factors compared.

About HeartBeam

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.